Select Publications
Journal articles
2024, 'Sodium Glucose Co-transporter 2 Inhibitors and Major Adverse Cardiovascular Outcomes: A SMART-C Collaborative Meta-Analysis.', Circulation, http://dx.doi.org/10.1161/CIRCULATIONAHA.124.069568
,2024, 'Focal Segmental Glomerulosclerosis Patient Baseline Characteristics in the Sparsentan Phase 3 DUPLEX Study', Kidney International Reports, 9, pp. 1020 - 1030, http://dx.doi.org/10.1016/j.ekir.2024.01.032
,2024, 'Barriers to Care: New Medications and CKD', Kidney International Reports, 9, pp. 504 - 507, http://dx.doi.org/10.1016/j.ekir.2023.12.012
,2024, 'Impact of Canagliflozin on Kidney and Cardiovascular Outcomes by Type 2 Diabetes Duration: A Pooled Analysis of the CANVAS Program and CREDENCE Trials', Diabetes Care, 47, pp. 501 - 507, http://dx.doi.org/10.2337/dc23-1450
,2024, 'Kidney Function, Albuminuria, and Risk of Incident Atrial Fibrillation: A Systematic Review and Meta-Analysis', American Journal of Kidney Diseases, 83, pp. 350 - 359.e1, http://dx.doi.org/10.1053/j.ajkd.2023.07.023
,2024, 'Targeting APRIL in the Treatment of IgA Nephropathy', Clinical Journal of the American Society of Nephrology, 19, pp. 394 - 398, http://dx.doi.org/10.2215/CJN.0000000000000338
,2024, 'VALOR-CKD: A Multicenter, Randomized, Double-Blind Placebo-Controlled Trial Evaluating Veverimer in Slowing Progression of CKD in Patients with Metabolic Acidosis', Journal of the American Society of Nephrology, 35, pp. 311 - 320, http://dx.doi.org/10.1681/ASN.0000000000000292
,2024, 'Daprodustat and Heart Failure in CKD.', J Am Soc Nephrol, http://dx.doi.org/10.1681/ASN.0000000000000321
,2024, 'Combination Treatment with Verinurad and Allopurinol in CKD: A Randomized Placebo and Active Controlled Trial.', J Am Soc Nephrol, http://dx.doi.org/10.1681/ASN.0000000000000326
,2024, 'Hypoglycemia and Cardiovascular Outcomes in the CARMELINA and CAROLINA Trials of Linagliptin A Secondary Analysis of Randomized Clinical Trials', JAMA Cardiology, 9, pp. 134 - 143, http://dx.doi.org/10.1001/jamacardio.2023.4602
,2024, 'Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and Albuminuria', Circulation, 149, pp. 450 - 462, http://dx.doi.org/10.1161/CIRCULATIONAHA.123.067584
,2024, 'Primary and Secondary Cardiovascular and Kidney Prevention With Canagliflozin: Insights From the CANVAS Program and CREDENCE Trial', Journal of the American Heart Association, 13, http://dx.doi.org/10.1161/JAHA.123.031586
,2024, 'Estimating the population-level impacts of improved uptake of SGLT2 inhibitors in patients with chronic kidney disease: a cross-sectional observational study using routinely collected Australian primary care data', The Lancet Regional Health - Western Pacific, 43, http://dx.doi.org/10.1016/j.lanwpc.2023.100988
,2024, 'The Prevalence of CKD in Australian Primary Care: Analysis of a National General Practice Dataset', Kidney International Reports, 9, pp. 312 - 322, http://dx.doi.org/10.1016/j.ekir.2023.11.022
,2024, 'Timing of statistical benefit of canagliflozin in patients with type 2 diabetes for cardiovascular and heart failure outcomes: Insights from the CANVAS Program and CREDENCE trial', Diabetes, Obesity and Metabolism, 26, pp. 758 - 762, http://dx.doi.org/10.1111/dom.15340
,2024, 'Combination therapy with kidney protective therapies: Optimizing the benefits?', Current Opinion in Nephrology and Hypertension, 33, pp. 136 - 143, http://dx.doi.org/10.1097/MNH.0000000000000929
,2024, 'Results of a randomized double-blind placebo-controlled Phase 2 study propose iptacopan as an alternative complement pathway inhibitor for IgA nephropathy', Kidney International, 105, pp. 189 - 199, http://dx.doi.org/10.1016/j.kint.2023.09.027
,2024, 'The Point-of-Care Peritoneal Dialysis System Early Evaluation Study (POC-PDEE): A pilot proof-of-principal study of the Ellen Medical Devices Point-of-Care affordable peritoneal dialysis system', Peritoneal Dialysis International, http://dx.doi.org/10.1177/08968608231209850
,2024, 'WCN24-847 SPARSENTAN VS IRBESARTAN IN PATIENTS WITH IMMUNOGLOBULIN A NEPHROPATHY (IgAN): SUBGROUP ANALYSES OF 2-YEAR RESULTS FROM THE PIVOTAL PHASE 3 PROTECT TRIAL', Kidney International Reports, 9, pp. S505 - S506, http://dx.doi.org/10.1016/j.ekir.2024.02.1413
,2023, 'Development and Validation of a New Hierarchical Composite End Point for Clinical Trials of Kidney Disease Progression', Journal of the American Society of Nephrology, 34, pp. 2025 - 2038, http://dx.doi.org/10.1681/ASN.0000000000000243
,2023, 'Effect of SGLT2 Inhibitors on Discontinuation of Renin–angiotensin System Blockade: A Joint Analysis of the CREDENCE and DAPA-CKD Trials', Journal of the American Society of Nephrology, 34, pp. 1965 - 1975, http://dx.doi.org/10.1681/ASN.0000000000000248
,2023, 'The effects of canagliflozin in type 2 diabetes in subgroups defined by population-specific body mass index: Insights from the CANVAS Program and CREDENCE trial', Diabetes, Obesity and Metabolism, 25, pp. 3724 - 3735, http://dx.doi.org/10.1111/dom.15267
,2023, 'Prevalence of systemic inflammation in individuals with atherosclerotic cardiovascular disease: baseline characteristics from the SELECT, SOUL and FLOW phase 3 trials of semaglutide', European Heart Journal, 44, http://dx.doi.org/10.1093/eurheartj/ehad655.2751
,2023, 'Abstract 17437: Estimated Lifetime Benefits of Combination Therapy With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Non-Steroidal MRAs in Patients With Type 2 Diabetes and Albuminuria', Circulation, 148, http://dx.doi.org/10.1161/circ.148.suppl_1.17437
,2023, 'Estimated lifetime benefit of novel pharmacological therapies in patients with type 2 diabetes and chronic kidney disease: A joint analysis of randomized controlled clinical trials', Diabetes, Obesity and Metabolism, 25, pp. 3327 - 3336, http://dx.doi.org/10.1111/dom.15232
,2023, 'The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease', Nephrology Dialysis Transplantation, 38, pp. 2041 - 2051, http://dx.doi.org/10.1093/ndt/gfad009
,2023, 'Cardiorenal Biomarkers, Canagliflozin, and Outcomes in Diabetic Kidney Disease: The CREDENCE Trial', Circulation, 148, pp. 651 - 660, http://dx.doi.org/10.1161/CIRCULATIONAHA.123.065251
,2023, 'Analysis of on-treatment cancer safety events with daprodustat versus conventional erythropoiesis-stimulating agents - post hoc analyses of the ASCEND-ND and ASCEND-D trials', Nephrology Dialysis Transplantation, 38, pp. 1890 - 1897, http://dx.doi.org/10.1093/ndt/gfac342
,2023, 'Kidney protection with canagliflozin: A combined analysis of the randomized CANVAS program and CREDENCE trials', Diabetes, Obesity and Metabolism, 25, pp. 2331 - 2339, http://dx.doi.org/10.1111/dom.15112
,2023, 'The sodium-glucose cotransporter-2 inhibitor canagliflozin does not increase risk of non-genital skin and soft tissue infections in people with type 2 diabetes mellitus: A pooled post hoc analysis from the CANVAS Program and CREDENCE randomized double-blind trials', Diabetes, Obesity and Metabolism, 25, pp. 2151 - 2162, http://dx.doi.org/10.1111/dom.15091
,2023, 'Canagliflozin, Blood Pressure Variability, and Risk of Cardiovascular, Kidney, and Mortality Outcomes: Pooled Individual Participant Data From the CANVAS and CREDENCE Trials', Journal of the American Heart Association, 12, pp. e028516, http://dx.doi.org/10.1161/JAHA.122.028516
,2023, 'A meta-analysis of GFR slope as a surrogate endpoint for kidney failure', Nature Medicine, 29, pp. 1867 - 1876, http://dx.doi.org/10.1038/s41591-023-02418-0
,2023, 'Effects of canagliflozin on cardiovascular and kidney events in patients with chronic kidney disease with and without peripheral arterial disease: Integrated analysis from the CANVAS Program and CREDENCE trial', Diabetes, Obesity and Metabolism, 25, pp. 2043 - 2047, http://dx.doi.org/10.1111/dom.15065
,2023, 'Effects of newer kidney protective agents on kidney endpoints provide implications for future clinical trials', Kidney International, 104, pp. 181 - 188, http://dx.doi.org/10.1016/j.kint.2023.03.037
,2023, 'Kidney and Cardiovascular Effects of Canagliflozin According to Age and Sex: A Post Hoc Analysis of the CREDENCE Randomized Clinical Trial', American Journal of Kidney Diseases, 82, pp. 84 - 96.e1, http://dx.doi.org/10.1053/j.ajkd.2022.12.015
,2023, '#3807 HEART FAILURE IN ASCEND-ND AND ASCEND-D', Nephrology Dialysis Transplantation, 38, http://dx.doi.org/10.1093/ndt/gfad063c_3807
,2023, '#4333 A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF BION-1301 IN ADULTS WITH IGA NEPHROPATHY', Nephrology Dialysis Transplantation, 38, http://dx.doi.org/10.1093/ndt/gfad063c_4333
,2023, 'Cardiorenal protective effects of canagliflozin in CREDENCE according to glucose lowering', BMJ Open Diabetes Research and Care, 11, pp. e003270, http://dx.doi.org/10.1136/bmjdrc-2022-003270
,2023, 'Design and population of the VALOR-CKD study: a multicenter, randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of veverimer in slowing progression of chronic kidney disease in patients with metabolic acidosis', Nephrology Dialysis Transplantation, 38, pp. 1448 - 1458, http://dx.doi.org/10.1093/ndt/gfac289
,2023, 'Glycemic Control and Effects of Canagliflozin in Reducing Albuminuria and eGFR: A Post Hoc Analysis of the CREDENCE Trial', Clinical journal of the American Society of Nephrology : CJASN, 18, pp. 748 - 758, http://dx.doi.org/10.2215/CJN.0000000000000161
,2023, 'Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial', The Lancet, 401, pp. 1584 - 1594, http://dx.doi.org/10.1016/S0140-6736(23)00569-X
,2023, 'Effects of canagliflozin on liver steatosis and fibrosis markers in patients with type 2 diabetes and chronic kidney disease: A post hoc analysis of the CREDENCE trial', Diabetes, Obesity and Metabolism, 25, pp. 1413 - 1418, http://dx.doi.org/10.1111/dom.14978
,2023, 'IgA Nephropathy Patient Baseline Characteristics in the Sparsentan PROTECT Study', Kidney International Reports, 8, pp. 1043 - 1056, http://dx.doi.org/10.1016/j.ekir.2023.02.1086
,2023, 'Targeting the Alternative Complement Pathway With Iptacopan to Treat IgA Nephropathy: Design and Rationale of the APPLAUSE-IgAN Study', Kidney International Reports, 8, pp. 968 - 979, http://dx.doi.org/10.1016/j.ekir.2023.01.041
,2023, 'Glucocorticoids for IgA nephropathy—pro', Kidney International, 103, pp. 666 - 669, http://dx.doi.org/10.1016/j.kint.2023.01.018
,2023, 'TREATMENT EFFECT OF CANAGLIFLOZIN FOR PATIENTS ON THERAPY FOR HEART FAILURE: POOLED ANALYSIS OF THE CANVAS PROGRAM AND CREDENCE TRIAL', Journal of the American College of Cardiology, 81, pp. 283, http://dx.doi.org/10.1016/s0735-1097(23)00727-1
,2023, 'Treatment effect of canagliflozin for patients on therapy for heart failure: Pooled analysis of the CANVAS program and CREDENCE trial', International Journal of Cardiology, 395, http://dx.doi.org/10.1016/j.ijcard.2023.131444
,2023, 'WCN23-0069 EFFICACY AND SAFETY OF REDUCED-DOSE ORAL METHYLPREDNISOLONE IN IGA NEPHROPATHY: THE TESTING TRIAL', Kidney International Reports, 8, pp. S51 - S52, http://dx.doi.org/10.1016/j.ekir.2023.02.118
,2023, 'WCN23-0412 EFFECT OF IPTACOPAN ON PROTEINURIA AND COMPLEMENT BIOMARKERS OVER TIME IN IgA NEPHROPATHY', Kidney International Reports, 8, pp. S271 - S272, http://dx.doi.org/10.1016/j.ekir.2023.02.612
,2023, 'WCN23-0574 THE ELLEN MEDICAL DEVICES AFFORDABLE POINT-OF-CARE PERITONEAL DIALYSIS SYSTEM - A PILOT STUDY', Kidney International Reports, 8, pp. S350 - S350, http://dx.doi.org/10.1016/j.ekir.2023.02.786
,